AU2007322068B2 - 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives as antitumor agents - Google Patents

5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives as antitumor agents Download PDF

Info

Publication number
AU2007322068B2
AU2007322068B2 AU2007322068A AU2007322068A AU2007322068B2 AU 2007322068 B2 AU2007322068 B2 AU 2007322068B2 AU 2007322068 A AU2007322068 A AU 2007322068A AU 2007322068 A AU2007322068 A AU 2007322068A AU 2007322068 B2 AU2007322068 B2 AU 2007322068B2
Authority
AU
Australia
Prior art keywords
compound
tumors
dimethylamino
methoxy
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007322068A
Other languages
English (en)
Other versions
AU2007322068A1 (en
Inventor
Chang-Ho Ahn
Won-Jea Cho
Young Bok Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus Genetics Inc
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of AU2007322068A1 publication Critical patent/AU2007322068A1/en
Priority to AU2012203232A priority Critical patent/AU2012203232B2/en
Application granted granted Critical
Publication of AU2007322068B2 publication Critical patent/AU2007322068B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007322068A 2006-11-17 2007-11-16 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives as antitumor agents Ceased AU2007322068B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012203232A AU2012203232B2 (en) 2006-11-17 2012-05-31 5, 6, or 7-substituted-S-(hetero)arylisoquinolinamine derivatives as antitumor agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86626906P 2006-11-17 2006-11-17
US60/866,269 2006-11-17
PCT/US2007/024041 WO2008063548A2 (en) 2006-11-17 2007-11-16 5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012203232A Division AU2012203232B2 (en) 2006-11-17 2012-05-31 5, 6, or 7-substituted-S-(hetero)arylisoquinolinamine derivatives as antitumor agents

Publications (2)

Publication Number Publication Date
AU2007322068A1 AU2007322068A1 (en) 2008-05-29
AU2007322068B2 true AU2007322068B2 (en) 2012-07-12

Family

ID=39430327

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2007322068A Ceased AU2007322068B2 (en) 2006-11-17 2007-11-16 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives as antitumor agents
AU2012203232A Ceased AU2012203232B2 (en) 2006-11-17 2012-05-31 5, 6, or 7-substituted-S-(hetero)arylisoquinolinamine derivatives as antitumor agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2012203232A Ceased AU2012203232B2 (en) 2006-11-17 2012-05-31 5, 6, or 7-substituted-S-(hetero)arylisoquinolinamine derivatives as antitumor agents

Country Status (13)

Country Link
US (2) US8034829B2 (enExample)
EP (2) EP2099765B1 (enExample)
JP (2) JP5270564B2 (enExample)
KR (1) KR101464591B1 (enExample)
CN (2) CN102532020B (enExample)
AU (2) AU2007322068B2 (enExample)
BR (1) BRPI0718841A2 (enExample)
CA (1) CA2669083C (enExample)
ES (1) ES2392361T3 (enExample)
IL (2) IL198571A (enExample)
MX (1) MX2009005242A (enExample)
PL (1) PL2099765T3 (enExample)
WO (1) WO2008063548A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034829B2 (en) * 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
FR2956816B1 (fr) 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
KR101641196B1 (ko) * 2014-09-18 2016-07-21 전남대학교산학협력단 헤테로아릴이소퀴놀린계 유도체 및 이를 포함하는 항암 조성물
US10341135B2 (en) * 2015-12-30 2019-07-02 Nova-Tron Controls Corp. Zone control system for conveyor system
JP7344486B2 (ja) * 2018-03-30 2023-09-14 国立大学法人京都大学 心筋細胞成熟促進剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1353508A (en) * 1971-09-09 1974-05-22 Koninklijke Pharma Fab Nv Aminoisoquinolines
KR20020074568A (ko) * 2001-03-20 2002-10-04 양지화학 주식회사 항암제로 유용한 3-아릴이소퀴놀린 유도체 및 그의 염

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US4942163A (en) * 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
WO2005075432A1 (ja) 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用
US8034829B2 (en) * 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1353508A (en) * 1971-09-09 1974-05-22 Koninklijke Pharma Fab Nv Aminoisoquinolines
KR20020074568A (ko) * 2001-03-20 2002-10-04 양지화학 주식회사 항암제로 유용한 3-아릴이소퀴놀린 유도체 및 그의 염

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cho et al., Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 24, 2003, pages 4451-4454 *
Cho et al., Bioorganic & Medicinal Chemistry, vol. 10, no. 9, 2002, pages 2953-2961 *
Kaiser et al., Synthesis, no. 11, 1974, pages 805-806 *
Van der Goot et al., European Journal of Medicinal Chemistry, vol. 10, no. 6, 1975, pages 603-606 *
Van der Got et al., Chimica Therapeutica, vol. 7, no. 3, 1972, pages 185-188 *

Also Published As

Publication number Publication date
AU2012203232B2 (en) 2014-10-09
CN102532020A (zh) 2012-07-04
JP2010510217A (ja) 2010-04-02
WO2008063548A2 (en) 2008-05-29
CN101573337B (zh) 2012-02-08
KR20090098821A (ko) 2009-09-17
JP2013151546A (ja) 2013-08-08
AU2007322068A1 (en) 2008-05-29
JP5668092B2 (ja) 2015-02-12
WO2008063548A3 (en) 2009-01-08
CN102532020B (zh) 2015-02-25
AU2012203232A1 (en) 2012-06-21
BRPI0718841A2 (pt) 2014-02-04
CA2669083C (en) 2014-10-28
US8314123B2 (en) 2012-11-20
JP5270564B2 (ja) 2013-08-21
IL223327A0 (en) 2013-02-03
EP2099765A2 (en) 2009-09-16
US20080182871A1 (en) 2008-07-31
CA2669083A1 (en) 2008-05-29
EP2099765B1 (en) 2012-08-29
US20120029012A1 (en) 2012-02-02
EP2423196A1 (en) 2012-02-29
US8034829B2 (en) 2011-10-11
ES2392361T3 (es) 2012-12-10
MX2009005242A (es) 2009-08-19
PL2099765T3 (pl) 2013-01-31
CN101573337A (zh) 2009-11-04
KR101464591B1 (ko) 2014-11-27
IL198571A (en) 2013-02-28
IL198571A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
JP5856843B2 (ja) ジケトピペラジンを用いた医薬組成物
AU2012203232B2 (en) 5, 6, or 7-substituted-S-(hetero)arylisoquinolinamine derivatives as antitumor agents
JP4596314B2 (ja) β−アラニン誘導体およびその用途
EP2014651A1 (en) Compounds and methods for modulating Rho GTPases
EP2650286A1 (en) Quinazoline derivatives and therapeutic use thereof
AU2014227992A1 (en) Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl) methanone compounds as cancer cell growth inhibitors
CN103429586A (zh) 哌嗪二酮化合物
WO2025118148A1 (en) Antioxidant drug-conjugate modulators of fpr1, compositions comprising the modulator, and methods of using the same
EP0639183B1 (en) Nitrogen oxides of aza- and diaza-anthracenedione derivatives, their preparation and their use as antitumor agents
AU7012500A (en) Phenanthroline-7-one derivatives and their therapeutic uses
KR20240014034A (ko) 헤테로비시클릭 화합물 및 그를 포함하는 약제학적조성물
ZA200601992B (en) CRF antagonists and heterobicyclic compounds
JP2004189659A (ja) 好中球エラスターゼ阻害剤を有効成分とする吸入剤
TW201315468A (zh) ２－芳基－４－喹唑啉酮化合物及其醫藥組合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired